The Buzz in. As Singapore continues to build its biomedical sciences sector into the. Singapore s Biotech industry
|
|
- Godfrey Cox
- 7 years ago
- Views:
Transcription
1 The Buzz in Singapore s Biotech industry Chan Yiu Lin Founder and Principal Consultant Greener Grass Communications As Singapore continues to build its biomedical sciences sector into the fourth pillar of its economy, there have been numerous developments in the biotechnology industry over the last several months. These developments includes strengthening Singapore s research and development (R&D) capabilities, translating research into new applications, encouraging industry developments, attracting top-notch scientific talents and establishing strong international linkages. These are summarized below. Strengthening R&D Capabilities The research institutes under the Biomedical Research Council (BMRC), continue to build upon their basic science capabilities and make significant research achievements in strategic areas, such as cancer, infectious diseases, genomics and medical devices. In addition, BMRC announced the results of its fourth grant call, where some 50 grants, amounting to S$29.2 million (US$18.2 million) in funding, were awarded to the wider scientific community of universities, hospitals and disease centers in Singapore. The results from the latest R&D survey show that R&D in Singapore continues to grow strongly. In 2004, the gross domestic expenditure on R&D (GERD) increased to S$4 062 million (US$2 540 million), led by the private sector, at 63.8% share. This brings the GERD to 2.25% of Singapore s GDP, which is on par with other advanced economies, including Belgium (2.42% in 2004), Taiwan (2.3% in 2002) and Switzerland (2.57% in 2000). The other factors demonstrating the progress of Singapore s R&D scene were an increase in number of researchers employed and a growth in the level of patenting activities. APBN Vol. 10 No
2 Research and innovation will be key drivers to transform the Singapore economy in the next years. Singapore has developed strong foundations in both the R&D industry and public sector research, said Mr Boon Swan Foo, managing director of Agency of Science Technology & Research (A*STAR), which released the 2004 R&D survey in October Corporate R&D laboratories and top R&D talents have been drawn to Singapore by the government s strong commitment to R&D and education, an attractive environment for R&D activities, and access to high quality, well-trained Singaporeans and foreign R&D talent. This strong government support for R&D is demonstrated by the launch of the Science & Technology Plan 2010 (STP2010) in February 06. The STP2010 has committed S$7.5 billion (US$4.7 billion) over the next five years, to sustain innovation-driven growth through R&D, with the aim of increasing national spending in R&D to 3% of GDP by The STP2010 will drive four key programs: Strengthening and deepening research capabilities; developing research talents in Singapore; promoting private sector R&D; and providing infrastructure support. The first program, strengthening and deepening research capabilities, is already well underway, with the opening of several research laboratories, over the last few months. In November 2005, the Chemical Synthesis Laboratory (CSL) was officially launched at the Biopolis and will provide a focal point to expand Singapore s chemicals capabilities and capacity to support the diverse chemical companies in their R&D work there. It will also help train the next generation of highly skilled PhD researchers to address the R&D manpower needs of the specialty chemicals and pharmaceutical industries. More recently, three new laboratories were opened in April 2006, to expand capabilities in bioimaging and stem cell research. Under the Singapore Bioimaging Consortium (SBIC), the Laboratory of Molecular Imaging will house bioimaging facilities, such as magnetic resonance imaging, optical and other imaging modalities, while the Laboratory of Metabolic Medicine will focus on research in diabetes, brain disorders and image-analysis. Under the Singapore Stem Cell Consortium (SSCC), the Laboratory for Stem Cell Biology will look at characterizing stem cells and will work together with the Stem Cell Bank to create a central pool of well-characterized stem cells for use by Singapore s research community. 408 APBN Vol. 10 No
3 During the opening of these three laboratories, Dr Balaji Sadasivan, Senior Minister of State for Health and Senior Minister of State for Information, Communications and the Arts, commented, It is hoped that the two consortia will catalyse the synergy amongst physical scientists, biologists, physicists, computer scientists, bioengineers and clinicians. By investing our resources in these areas of translational research, we hope that the work of SBIC and SSCC will lead to new clinical opportunities and improvements in diagnosis and treatment of diseases. Ultimately, this will lead to improvements in the health of Singaporeans. Translating R&D into New Applications Not only will these labs build up key research capabilities, they will also help to bridge the gap between basic research and clinical applications. This is a key strategy in Singapore s efforts in boosting translational medicine, which transforms laboratory discoveries into better ways to diagnose and treat patients. Translational medicine builds upon Singapore s strong R&D foundations, leading to new medical applications. This will improve patient outcomes, improve the healthcare system and help to save lives. In October 2005, the BMS International Advisory Panel endorsed four new translational initiatives. The Singapore Stem Cell Consortium will advance stem cell therapies by coordinating and funding both basic and clinic stem cell research in Singapore. It will also establish key infrastructure support, develop talents and establish partnership programs. The Singapore Immunology Network will build up Singapore s immunological expertise and develop international linkages with leading institutions. The Singapore Consortium of Cohort Studies facilitates research in the complex geneenvironment interactions in diseases, aiming to influence lifestyle changes, improve clinical outcomes and enhance human healthcare. Lastly, A*STAR s Data Privacy Framework protects the privacy and confidentiality of subjects and patients involved in projects, ensuring that research is carried out in an ethical manner. Realizing the that good translational medicine requires a new breed of researchers that have both research and clinical experience, in January 2006, the Biomedical Research Council (BMRC) and the National Medical Research Council (NMRC) supported the second batch of doctors under the Clinician-Scientist Investigator (CSI) Award. This award encourages translational medicine by supporting the career development of clinician scientists, who are undertaking research in areas as diverse as neurology, orthopaedic surgery, stem cell biology, cancer biology and genetic study on human obesity. APBN Vol. 10 No
4 I am very excited at the opportunities that this award will provide. I will get to work closely with basic scientists. I can focus my effort on stem cell research and its use in repairing cartilage and meniscus and hopefully find the solution for patients who suffer from debilitating knee pain, said Associate Professor Hui Hoi Po, James, one of the senior clinician scientists receiving the CSI award. Attracting Scientific Talents In addition to building up capabilities amongst its local manpower pool, Singapore has been successful in attracting top calibre scientists. In early 2006, Drs Neal Copeland and Nancy Jenkins, joined the Institute of Molecular and Cell Biology (IMCB). Prior to IMCB, they were both world-renowned cancer geneticists at the US National Cancer Institute (NCI) and the husband-and-wife team are amongst the world s most highly cited scientists. In April 2006, four eminent scientists were appointed in key positions within Singapore s biomedical sciences industry. Professor Birgitte Lane has taken over the helm of the Centre for Molecular Medicine (CMM), which focuses on Epithelial Biology, Genetic Medicine, Virology, Regenerative Medicine and the Singapore OncoGenome Project. Professor Philippe Kourilsky has been appointed as the chairman of the Singapore Immunology Network, where his leadership will be critical in shaping the establishment of its research programs and infrastructure, as well as establishing immunology as a core capability in Singapore s biomedical science research. He is a noted expert in molecular immunology and tumour immunity, and also holds the chair of Molecular Immunology at the College de France. Professor Edward Holmes will be appointed as the executive deputy chairman for Clinical-Translational Sciences at the Biomedical Research Council. He is currently the vice chancellor for Health Sciences and dean, School of Medicine, at the University of California, San Diego (UCSD). Professor Judith Swain will be the founding executive director of the proposed Singapore Institute for Clinical Sciences (SICS), which will focus on clinical and translational research, bridging basic biomedical research and healthcare for patients. I am excited to join my colleagues in Singapore in building a world-class research program in clinical and translational medicine, said Professor Swain. By taking advantage of the strengths in biomedical research in Singapore, the excellent base of clinical investigators and the robust and varied patient population served by the hospitals under the Ministry of Health, Singapore can become a leading hub for clinical sciences and the development of new therapies. 410 APBN Vol. 10 No
5 Industry Developments In addition to scientific talents making Singapore their home, a number of international companies have also chosen to establish their base here, helping to build up strong industry capabilities. In January 2006, CombinatoRx Singapore was set up. It will leverage upon the high throughput screening technology of CombinatoRx Incorporated, to discover and potentially develop novel product candidates to treat infectious diseases, with an initial focus on hepatitis C and hepatitis B. It will also help to position Singapore as a source of innovative new therapeutics to address the large infectious disease market. The formation of CombinatoRx Singapore is designed to address a significant global health need by advancing the development of novel therapeutics for infectious disease, while also acting as a gateway for CombinatoRx to the Asian scientific and business communities, said Mr Alexis Borisy, president and CEO of CombinatoRx. We chose Singapore because of the availability of world class scientific and clinical talents in infectious diseases, developed intellectual property and regulatory infrastructure and most importantly, the Singapore government s commitment to the biomedical sciences industry. In February 2006, Bio*One Capital and the Lonza Group announced that they are jointly building a large-scale mammalian cell culture plant in Singapore for the manufacture of commercial biopharmaceuticals, totalling an investment of US$250 million. This project will support efforts to expand the biomedical sciences industry here, through attracting more biopharmaceuticals manufacturing activities. As Singapore becomes a major production hub for pharmaceuticals, biopharmaceuticals and medical devices, companies like SGS, the world s leading inspection, verification, testing and certification company, are attracted here. In March 2006, SGS opened its new Singapore QC laboratory, dedicated to quality control testing of pharmaceuticals, biopharmaceuticals and medical devices. This will develop Singapore s strong base of services providers that support biomedical manufacturers. Local companies have also been making significant developments. Home-grown start-up, Veredus Laboratories launched one of the world s first commercially available avian influenza diagnostic kits, which uses proprietary nucleic acid diagnostic primers developed by the Genome Institute of Singapore (GIS). Veredus Laboratories then went on to partner STMicroelectronics to develop a rapid-detection, point-of-need, lab-on-chip to diagnose avian flu within approximately one hour of testing. Over the last few months, MerLion Pharmaceuticals, a Singaporebased drug discovery company has established international research collaborations with companies and organizations, including the US National Cancer Institute, Astellas Pharma and the Novartis Institute of Tropical Diseases. APBN Vol. 10 No
6 International Linkages As world-leading companies continue to set up operations here, and more global partnerships are established with Singapore-based companies, the nation s international linkages will strengthen. Realizing that science cannot occur in isolation, Singapore is proactively building up its global linkages. In October 2005, A*STAR and the Karolinska Institutet, one of Europe s largest medical universities, agreed to offer joint PhD training in the biomedical sciences. A few months later, A*STAR made a similar agreement with the University of Dundee, one of Europe s leading universities in biomedical sciences. In addition to partnering with these world-class universities, these collaborations will open new opportunities for research collaborations between Singapore and Sweden and Scotland. In November 2005, BioSingapore and AusBiotech, life science industry associations in Singapore and Australia respectively, agreed to promote collaborations between their members. This includes industry development and personal interactions amongst companies and organizations. Another long term collaboration was also formed between A*STAR, the National University of Singapore and the University of California, San Diego. Under this biomedical sciences research collaboration, six projects will be initiated in the areas of host-pathogen interactions, cancer, stem cell biology and developmental biology. Contact Details Chan Yiu Lin Founder and Principal Consultant of Greener Grass Communications (GGC) Tel: Fax: yiulin@starhub.net.sg URL: Looking Ahead Singapore has been forging ahead, establishing more of such linkages with other international biotech hotspots. Singapore s Biopolis was recently identified by FierceBiotech, an international newsletter for the biotech industry, as the fourth region that is bestpositioned to become a hotbed of biotech innovation. Furthermore, the expansion of the Biopolis, which should be completed by end 2006, has already confirmed Singapore s growing role as a global biomedical sciences hub. Looking ahead, Singapore will continue to build upon its strong foundations in the biomedical sciences area, strengthening its capabilities in translational and clinical research, with the objective of improving human healthcare. 412 APBN Vol. 10 No
Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure
Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National
More informationClinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters. www.asiabiotech.com
Clinical Trials In Singapore Dr Say-Beng Tan, Dr Eugene Fidelis Soh, and Dr Han-Chong Toh Introduction Clinical trials are the gold standard for the evaluation of new treatment strategies. New treatments
More informationHong Kong Poised to be the Asia s Biotechnology Hub
Think Asia, think Hong Kong - London 13-09-2011 www.hkbio.org.hk BioTech at Science Park Your Safe and Fast Track to China Hong Kong Poised to be the Asia s Biotechnology Hub Albert Cheung Hoi Yu, Ph.D.
More informationCareer Opportunities within the French Alliance for Life and Health Sciences
1 Career Opportunities within the French Alliance for Life and Health Sciences Mireille Guyader, PhD Director, Inserm-USA Office INSERM KEY FIGURES (Year 2013) Budget: 970 M (~ $1.2 Billion) Human resources:
More informationMaster of Science in Biomedical Sciences
Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving
More informationEMBARGOED 11 NOVEMBER FURTHERR. therapies. Research. Technology and. same time, Page 1 of
MEDIA RELEASE EMBARGOED UNTIL 11 NOVEMBER 2015, 1100H SST 11 NOVEMBER 2015 A*STAR AND NUS LAUNCH JOINT IMAGING CENTRE TO TRANSLATIONAL CLINICAL RESEARCH National platform for research imaging to study
More informationIntroduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)
Overview of the Healthcare Policy Introduction For Japan, which is becoming an ultra-aging society ahead of other countries, it is important to realize the world s most advanced medical technologies and
More informationTHE LINCOLN INSTITUTE OF HEALTH
THE LINCOLN INSTITUTE OF HEALTH Background The Chair in the Care of the Older Person will be part of the new Lincoln Institute of Health, a cross disciplinary research collaboration linking schools, colleges
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationMolecular Biotechnology Master s Degree Program
> APPLIED LIFE SCIENCES Master s Degree Program: > FULL TIME Molecular Biotechnology Master s Degree Program www.fh-campuswien.ac.at My Occupational Future. Your Career Opportunities Biotechnology is one
More informationThe majority of pharmaceutical companies in
Pharmaceutical Infrastructure and Industry Professor Che-Ming Teng, Ph.D. National Taiwan University College of Medicine, Taipei, Taiwan The majority of pharmaceutical companies in Taiwan are devoted to
More informationIl ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020
Il ruolo dell Advisory Group for «Health, Wellbeing and Demographic Change» in Horizon 2020 Lucia Monaco Horizon 2020 Advisory Group, Societal Challenges 1: Health, Demographic Change and Wellbeing Seminario:
More informationITT Advanced Medical Technologies - A Programmer's Overview
ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More informationUniversity Medical Centres
University Medical Centres in the Netherlands AMC UMC Utrecht University Medical Centres University Medical Centres and the Health System Reform in the Netherlands: a Position Paper In the last ten years
More informationThe National Institute of Genomic Medicine (INMEGEN) was
Genome is...... the complete set of genetic information contained within all of the chromosomes of an organism. It defines the particular phenotype of an individual. What is Genomics? The study of the
More informationClinician Investigator Program
Clinician Investigator Program Queen s Clinician Investigator Program: Developing the next Overview The Queen s University Clinician Investigator Program (CIP) is an intensive, research-based postgraduate
More informationSACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS
SACKLER SCHOOL OF GRADUATE BIOMEDICAL SCIENCES CATALOG 2015-2016 PROGRAMS OF STUDY, COURSES AND REQUIREMENTS FOR ALL GRADUATE PROGRAMS Graduate Programs CELL, MOLECULAR, AND DEVELOPMENTAL BIOLOGY CLINICAL
More informationInformation for patients and the public and patient information about DNA / Biobanking across Europe
Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes
More informationPharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More information[ Special Feature ] An Exclusive Interview with Executive Vice Dean of Graduate Medical School Singapore, Dr Ranga Krishnan
An Exclusive Interview with Executive Vice Dean of Graduate Medical School Singapore, Dr Ranga Krishnan www.asiabiotech.com Volume 12 > Number 2 > 2008 Wanda Tan, editor (World Scientific Publishing) interviewing
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationPolicy statement. Stem cell research
Policy statement Stem cell research Introduction For some people who survive a heart attack, the damage to their heart muscle can lead to debilitating heart failure, for which there is no cure. Nearly
More informationLoma Linda University and Siemens PETNET Solutions, Inc.
Loma Linda University and Siemens PETNET Solutions, Inc. announce operational state-of-theart PET production and research facility to advance molecular imaging FOR IMMEDIATE RELEASE CONTACT: Susan Onuma
More informationMaster of Science in Biochemistry (Molecular Medicine Option).
Master of Science in Biochemistry (Molecular Medicine Option). Molecular medicine is a specialized area of medicine. Its main thrust is to understand the molecular and cellular basis of disease. Understanding
More informationGraduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine
Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine Graduate Certificate in Metabolic & Nutritional Medicine Graduate Certificate Metabolic & Nutritional Medicine Purpose
More informationGenetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association
6 Genetic testing The difference diagnostics can make The British In Vitro Diagnostics Association Genetic INTRODUCTION testing The Department of Health published Our Inheritance, Our Future - Realising
More informationMcMASTER SCHOOL OF BIOMEDICAL ENGINEERING. http://bme.mcmaster.ca
McMASTER SCHOOL OF BIOMEDICAL ENGINEERING http://bme.mcmaster.ca A wide gap currently exists between researchers trained in life sciences and those trained in engineering a gap that represents an impediment
More informationAPPENDIX C: ACADEMIC MISSION STATEMENT
APPENDICES APPENDIX C: ACADEMIC MISSION STATEMENT The University of California, San Francisco shares the University s mission of achieving excellence in education, research, and public service. As a graduate
More informationRoche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
More informationLIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld
LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationAutomating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se
Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in
More informationMediSapiens Ltd. Bio-IT solutions for improving cancer patient care. Because data is not knowledge. 19th of March 2015
19th of March 2015 MediSapiens Ltd Because data is not knowledge Bio-IT solutions for improving cancer patient care Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2015 MediSapiens Ltd. All
More informationThe Ohio State University College of Medicine. Biomedical Sciences Graduate Program (BSGP) The Biology of Human Disease. medicine.osu.
(BSGP) The Biology of Human Disease medicine.osu.edu/bsgp Welcome from BSGP Leadership Thank you for your interest in the at The Ohio State University Wexner Medical Center. Our goal is to train talented,
More informationCDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis
CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society
More informationThe Texas Biotechnology Industry
The Texas Biotechnology Industry 2014 Fortune 1000 company NBTY opens state-of-the-art vitamin manufacturing plant in San Antonio See Page 15 Allergan installs new production line at Waco pharmaceutical
More informationA*STAR. to Partnership IMB
A*STAR welcomes EPFL to Partnership IMB 7 hr flight radius of half the world s population Singapore: The Biopolis of Asia An International Biomedical Sciences Cluster Advancing Human Health and Creating
More informationHand in Hand with SingHealth Foundation
Hand in Hand with SingHealth Foundation SINGHEALTH FOUNDATION is a not-for-profit organisation committed to actively raising funds to support healthcare programmes in its four core areas of Cord Blood
More informationFACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
More informationwww.uea.ac.uk/pha WHAT WILL YOU DISCOVER?
www.uea.ac.uk/pha WHAT WILL YOU DISCOVER? PHARMACOLOGY AND DRUG DISCOVERY UNDERGRADUATE COURSES 2016 WELCOME JOIN US ON A UNIQUE COURSE DESIGNED TO PRODUCE THE UK S NEXT LEADERS IN DRUG DISCOVERY. 1 1
More informationThe Cell Therapy Catapult
The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing
More informationABOUT THE KEYNOTE SPEAKERS. Prof Donald Tan
ABOUT THE KEYNOTE SPEAKERS Prof Donald Tan Prof Donald Tan is a Senior Advisor for Singapore National Eye Centre (SNEC) and SingHealth, Chairman of the Singapore Eye Research Institute (SERI), Professor
More informationWelcome Address by the. State Secretary at the Federal Ministry of Education and Research. Dr Georg Schütte
Welcome Address by the State Secretary at the Federal Ministry of Education and Research Dr Georg Schütte at the "Systems Biology and Systems Medicine" session of the World Health Summit at the Federal
More informationEditorial. Yves Levy, Executive Director
Editorial Yves Levy, Executive Director I am delighted to announce the creation of a new research centre: the Vaccine Research Institute (VRI). The VRI addresses the unprecedented challenge of developing
More informationTechnological Advances in the Medical Field, Human Health and Aging
1 EGN 1033 Technology Humans and Society Technological Advances in the Medical Field, Human Health and Aging Tatiana Fuentes Daniel Garcia Beatriz Varela Florida International University 10555 West Flagler
More informationSingapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study
JOINT PRESS RELEASE EMBARGO TILL 7 August 2007, 1130 HOURS Singapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study A Singapore team of physician
More information2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative
Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life
More informationBOOSTING THE COMMERCIAL RETURNS FROM RESEARCH
BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH Submission in response to the Discussion Paper November 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health
More informationJanssen Research & Development 3210 Merryfield Row San Diego, CA 92121
NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks
More informationThis is GE Healthcare
This is GE Healthcare An Overview Imagination at work Last updated July 2014 General Electric: A heritage of innovation Founded by Thomas Edison in 1878 Only company from the original 1896 Dow Jones index
More informationHuman Health Sciences
Human Health Sciences WITH PLYMOUTH UNIVERSITY DISCOVER MORE If you would like to visit Plymouth and meet our staff, then why not come along to one of our open days. Human Health Sciences WITH PLYMOUTH
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationPharmaceutical & Chemical Sciences Graduate Program
Pharmaceutical & Chemical Sciences Graduate Program Pharmaceutical and Chemical Sciences Graduate Program Program Goals and Design: The mission of the Pharmaceutical and Chemical Sciences Graduate Program
More informationCAMPAIGN: Transforming MEDICINE Beyond IMAGINATION
Our CAMPAIGN: Transforming MEDICINE Beyond IMAGINATION The School of Medicine Research Building: Health Sciences Facility III A MESSAGE from DEAN REECE Consider for a moment this question what shapes the
More informationPersonalized medicine in China s healthcare system
Personalized medicine in China s healthcare system Jingmin Kan, Sam Linsen Netherlands office for Science and Technology, Guangzhou and Shanghai, China Content PERSONALIZED MEDICINE 2 FOCUS AT THE INDIVIDUAL
More informationPanel discussions Friday, October 4, 2013. Panelists
Panel discussions Friday, October 4, 2013 Career Options with a Graduate Degree in Psychological Sciences: Learning from Alumni Experiences 10:30 11:30 a.m., 498 Bluemont Hall Mitch Brigell, PhD 1977 Director
More informationNurse Researcher or Clinical Research Nurse: Understanding the Difference
Nurse Researcher or Clinical Research Nurse: Understanding the Difference Claudia D. Smith, PhD, RN, NE-BC Director, Nursing Research St. Luke s Medical Center An Alternate Title for the Presentation:
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Diego Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Diego Metropolitan Statistical Area Overview and History of Biotechnology in San Diego San Diego has a significant concentration of
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationCAREERS IN BIOMEDICAL SCIENCE & THE IBMS. Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire
CAREERS IN BIOMEDICAL SCIENCE & THE IBMS Betty Kyle Scottish Regional Representative IBMS Lead Biomedical Scientist NHS Lanarkshire What is a biomedical scientist? Biomedical scientists carry out investigations
More informationDonna J. Dean, Ph.D. October 27, 2009 Brown University
Building Connections with NIH Program Officers: Myths and Realities Donna J. Dean, Ph.D. October 27, 2009 Brown University Funding Agencies Federal Agencies Focused on Biomedical Research s of Health (NIH)
More informationSEQUENCING INITIATIVE SUOMI (SISU) SYMPOSIUM SPEAKERS August 26, 2014
SEQUENCING INITIATIVE SUOMI (SISU) SYMPOSIUM SPEAKERS August 26, 2014 Professor Aarno Palotie Professor Aarno Palotie is the Research Director of the Human Genomics program at the Finnish Institute for
More informationChildren and Families Commission 714-834-5186 (office) 714-390-9567 (Cell) 949-824-6455
FOR IMMEDIATE RELEASE December 13, 2012 CONTACT: Kelly Pijl Tom Vasich Children and Families Commission UC Irvine 714-834-5186 (office) 714-390-9567 (Cell) 949-824-6455 Kelly.Pijl@cfcoc.ocgov.com tmvasich@uci.edu
More informationTO MEMBERS OF THE COMMITTEE ON EDUCATIONAL POLICY AND THE COMMITTEE ON HEALTH SERVICES: ACTION ITEM
Office of the President TO MEMBERS OF THE COMMITTEE ON EDUCATIONAL POLICY AND THE COMMITTEE ON HEALTH SERVICES: ACTION ITEM For Meeting of POWERPOINT PRESENTATIONS: ONE TWO APPROVAL TO PROCEED WITH THE
More informationSupport Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:
More informationEarly Phase Clinical Drug Development
Massachusetts College of Pharmacy and Health Sciences, Worcester, MA Post-PharmD Fellowship Program at Novartis Institutes for BioMedical Research, Cambridge, MA Early Phase Clinical Drug Development Introduction
More informationHow Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
More informationStem Cells Market Trends based on Primary Industry Analysis
GENReports: Market & Tech Analysis Stem Cells Market Trends based on Primary Industry Analysis > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us > Gary Oosta,
More informationDeals Profiled. M&A Activity. Sector Acquirer Target. In this Issue: M&A Snapshot Information Technology Medical Devices Biotechnology Pharmaceuticals
In this Issue: M&A Snapshot Information Technology Medical Devices Biotechnology Pharmaceuticals Deals Profiled Sector Healthcare-IT Intuit Medfusion Biotechnology PerkinElmer, Inc. Signature Genomics
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationVISION STATEMENT. Guiding principles:
VISION STATEMENT Overview The University of Nevada, Las Vegas (UNLV) School of Medicine will address the well-identified need to further advance healthcare in Southern Nevada and establish the foundation
More informationBS in Pharmaceutical Science (BSPS) degree program University of Rhode Island
To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,
More informationLife writes the questions We pursue the answers
Life writes the questions We pursue the answers Life writes the questions. 1 What will help me? Can I have hope? When will the others notice? How much life is six months? How bad can it get? Am I alone?
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationMr. Philip Yeo. Medical Technologies Investment Company (MTIC) Holdings Pte Ltd,
Mr. Philip Yeo Mr. Philip Yeo is Chairman, SPRING Singapore, the Singapore Government s development agency with the mission of enabling and growing Local Enterprises especially Small and Medium Enterprises.
More informationAnforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research
Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from
More informationProfessional Science Masters Degrees. What are PSM degrees?
Professional Science Masters Degrees Charles E. Schmidt College of Science Presentation to FAU Board of Trustees April 21, 2010 by Dean Gary W. Perry What are PSM degrees? Professional Science Master programs
More informationUCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA
UCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA Dr. Henry Daniell Pegasus Professor & University Board of Trustee Chair Dept. Mol.
More informationVision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision
Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision Medicine Initiative: Building a Large U.S. Research Cohort
More informationQuality assurance of doctoral education in an interfacultary Graduate School
Quality assurance of doctoral education in an interfacultary Graduate School Utrecht University Graduate school of Life Sciences Utrecht, The Netherlands Saskia Ebeling PhD Administrative Secretary to
More information1. What are the key strengths and weaknesses of the UK s innovation system in relation to business-university collaboration?
ABPI S RESPONSE TO THE BUSINESS, INNOVATION AND SKILLS SELECT COMMITTEE INQUIRY INTO THE STRENGTHS AND WEAKNESSES OF BUSINESS-UNIVERSITY COLLABORATION IN THE UK AND THE UK S PERFORMANCE AGAINST INTERNATIONAL
More informationFonds de recherche du Québec - Santé AN OVERVIEW
Fonds de recherche du Québec - Santé AN OVERVIEW THE CHIEF SCIENTIST OF QUÉBEC Rémi Quirion is the Chief Scientist of Québec. His position at the interface of the three research funds enables him to build
More information1. Program Title Master of Science Program in Biochemistry (International Program)
1 Program Structure and Specification Master of Science Program in Biochemistry (International Program) Curriculum Last Revised in 2012 for Students Entering in Academic Year 2016 -----------------------------------------
More informationCANADA: A WORLD LEADING LOCATION TO CONDUCT CLINICAL TRIALS
CANADA: A WORLD LEADING LOCATION TO CONDUCT CLINICAL TRIALS Canada is a world leading location for pharmaceutical and medical device companies to conduct their clinical trials. Both publicly available
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationPhD training at Masaryk University national system and institutional progress
PhD training at Masaryk University national system and institutional progress Tarragona, June 2016 2% of GDP on R & D (=85 billions CZK/year) 50% from industry/50% from government and SF (infrastructures)
More informationRECOMMEND APPROVAL OF MASTER OF SCIENCE IN BIOMEDICAL SCIENCE AND BIOTECHNOLOGY AT UNIVERSITY OF COLORADO DENVER
Page 1 of 5 TOPIC: PREPARED BY: RECOMMEND APPROVAL OF MASTER OF SCIENCE IN BIOMEDICAL SCIENCE AND BIOTECHNOLOGY AT UNIVERSITY OF COLORADO DENVER IAN MACGILLIVRAY, DIRECTOR OF ACADEMIC AFFAIRS I. SUMMARY
More informationPositions Available in SINAPSE INSTITUTE in Singapore
Positions Available in SINAPSE INSTITUTE in Singapore The SINAPSE Institute (www.sinapseinstitute.org), under the direction of Prof. Nitish Thakor (www.jhu.edu/nthakor), is a newly launched research institute
More informationIncreasing Innovation in R&D - Seizing early stage external growth opportunities
Increasing Innovation in R&D - Seizing early stage external growth opportunities Paul R. Eynott, PhD sanofi-aventis, US paul.eynott@sanofi-aventis.com -1- Sommaire -2- CHRISTOPHER A. VIEHBACHER Chief Executive
More informationLocation for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014
Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying
More informationThe Healing Power of Data
The Healing Power of Data The Healing Power of Data A Message from the Dean and Vice President for Health Sciences Imagine living in a world in which: a mobile device predicts when you are at high risk
More informationThe Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry
Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge
More informationHealthcare Innovation: Industry Challenges Being Addressed by Global One Hitachi
636 Hitachi Review Vol. 64 (2016), No. 10 Overview Healthcare Innovation: Industry Challenges Being Addressed by Global One Hitachi Harry Reddy, MS, MEng., MBA, Ph.D. (cont.) Tomoyoshi Takeo CHANGES SOUGHT
More informationInternational training programme
International training programme Science has no native land, as knowledge is the heritage of humankind, the torch that lights up the world. Louis Pasteur The Institut Pasteur International Network (RIIP)
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many
More informationGRADUATE CATALOG LISTING
GRADUATE CATALOG LISTING 1 BIOINFORMATICS & COMPUTATIONAL BIOLOGY Telephone: (302) 831-0161 http://bioinformatics.udel.edu/education Faculty Listing: http://bioinformatics.udel.edu/education/faculty A.
More information